BACTERIOSTATIC WATER FOR INJECTION IN PLASTIC CONTAINER Drug Patent Profile

When do Bacteriostatic Water For Injection In Plastic Container patents expire, and when can generic versions of Bacteriostatic Water For Injection In Plastic Container launch?

Bacteriostatic Water For Injection In Plastic Container is a drug marketed by Abraxis Pharm and Hospira and is included in three NDAs.

The generic ingredient in BACTERIOSTATIC WATER FOR INJECTION IN PLASTIC CONTAINER is sterile water for injection. There are one thousand and seventy-two drug master file entries for this compound. Nineteen suppliers are listed for this compound. Additional details are available on the sterile water for injection profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Bacteriostatic Water For Injection In Plastic Container

A generic version of BACTERIOSTATIC WATER FOR INJECTION IN PLASTIC CONTAINER was approved as sterile water for injection by HOSPIRA on October 27^th, 1982.

Summary for BACTERIOSTATIC WATER FOR INJECTION IN PLASTIC CONTAINER

US Patents:	0
Applicants:	2
NDAs:	3
Finished Product Suppliers / Packagers:	5
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	60
DailyMed Link:	BACTERIOSTATIC WATER FOR INJECTION IN PLASTIC CONTAINER at DailyMed

Recent Clinical Trials for BACTERIOSTATIC WATER FOR INJECTION IN PLASTIC CONTAINER

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
University of Plymouth	EARLY_PHASE1
National University Hospital, Singapore	PHASE2
National Medical Research Council (NMRC), Singapore	PHASE2

See all BACTERIOSTATIC WATER FOR INJECTION IN PLASTIC CONTAINER clinical trials

US Patents and Regulatory Information for BACTERIOSTATIC WATER FOR INJECTION IN PLASTIC CONTAINER

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Abraxis Pharm	BACTERIOSTATIC WATER FOR INJECTION IN PLASTIC CONTAINER	sterile water for injection	LIQUID;N/A	089099-001	Dec 29, 1987		DISCN	No	No
Abraxis Pharm	BACTERIOSTATIC WATER FOR INJECTION IN PLASTIC CONTAINER	sterile water for injection	LIQUID;N/A	089100-001	Dec 29, 1987		DISCN	No	No
Hospira	BACTERIOSTATIC WATER FOR INJECTION IN PLASTIC CONTAINER	sterile water for injection	LIQUID;N/A	018802-001	Oct 27, 1982	AP	RX	Yes	Yes

Market Dynamics and Financial Trajectory for Bacteriostatic Water for Injection in Plastic Containers

Last updated: February 9, 2026

Market Overview

Bacteriostatic Water for Injection (BWFI) in plastic containers occupies a niche within the sterile injectable solutions segment, primarily used as a diluent for antibiotics, anesthetics, and other medications requiring reconstitution. The global market for BWFI is driven by increased demand for sterile injectable drugs, the rising prevalence of chronic diseases, and expanding healthcare infrastructure in emerging markets.

Market Size and Growth Projections

The global BWFI market was valued at approximately USD 400 million in 2022. It is projected to grow with a compound annual growth rate (CAGR) of around 6.2% through 2027, reaching an estimated USD 560 million by 2027.[1] This growth rate exceeds that of the broader sterile injectable segment (approx. 4-5%), reflecting heightened demand for specialized diluents compatible with single-use plastic containers.

Factors contributing to market expansion include:

• Regulatory shifts and standards: stricter sterility protocols facilitate increased adoption of pre-filled, ready-to-use formulations.
• COVID-19 pandemic: acceleration in vaccine and therapeutic development led to higher utilization of sterile solutions.
• Advances in plastic container technology: improved barrier properties extend product shelf life and safety, boosting demand.

Key Market Drivers

1. Increased Adoption in Hospitals and Clinics: As healthcare moves toward outpatient and home-based infusion therapies, BWFI in plastic containers offers convenience, sterility, and compatibility with portable infusion devices.

2. Regulatory Approvals and Standards: Agencies like the FDA and EMA emphasize high-quality, pre-sterilized, single-use containers, elevating demand for BWFI that meet such specifications.

3. Innovation in Packaging: Use of high-quality plastics reduces extractables and leachables, enhances stability, and permits longer shelf life, fostering market growth.

4. Emerging Markets Expansion: Countries such as China, India, and Brazil experience rapid healthcare infrastructure development, increasing volumes of sterile solutions use.

Market Segmentation

• Container Type: Plastic containers dominate, capturing over 85% of the market owing to their lightweight, cost-efficiency, and lower breakage rates compared to glass.
• End-User: Hospitals and clinics represent the primary consumers, accounting for circa 70% of demand, with emerging growth in pharmaceutical manufacturing sectors.
• Geography: North America holds approximately 40% market share, followed by Europe at 30%. Asia-Pacific shows the fastest growth, at CAGR of approximately 8%, driven by increased healthcare spending.

Competitive Landscape

Major players include:

• Baxter International
• B. Braun Melsungen AG
• Pfizer Inc.
• Fresenius Kabi
• Narang Medical Ltd.

Innovation focuses on enhanced plastic barrier properties, sterile manufacturing processes, and digital tracking systems. Market entry barriers include stringent regulatory requirements and high initial R&D costs.

Regulatory and Policy Environment

Stringent Good Manufacturing Practices (GMP) and sterilization mandates influence product specifications and manufacturing processes. Regulatory agencies mandate validation of sterilization and preservative efficacy, influencing product design and market entry costs.

Financial Trajectory and Investment Outlook

Investment in R&D for preservative-free formulations and eco-friendly plastics is on the rise. Companies investing in high-barrier plastics and integrated manufacturing solutions aim for higher margins and enhanced market share.

Market penetration strategies include:

• Partnering with healthcare providers for direct distribution.
• Developing novel preservative-free formulations compatible with plastic containers.
• Expanding manufacturing capacity in high-growth regions.

Expected capital expenditure for key players ranges from USD 50 million to USD 200 million over three years, aimed at expanding capacity and upgrading facilities to meet emerging standards.

Risks and Challenges

• Regulatory barriers: Navigating complex approval processes adds cost and delays.
• Material integrity issues: Ensuring plastic container compatibility and preventing leachables.
• Supply chain vulnerabilities: Raw material shortages or disruptions can impact production.

Key Takeaways

• The BWFI market in plastic containers is poised for steady, above-average growth driven by healthcare infrastructure expansion and technological advancements.
• North America leads, but Asia-Pacific offers the fastest growth.
• Major investments focus on high-quality plastics, preservative-free options, and upgrading manufacturing capabilities.
• Regulatory compliance remains a critical factor affecting market entry and product development.
• Market expansion relies on innovation, strategic partnerships, and addressing supply chain risks.

FAQs

1. What are the main applications of bacteriostatic water in plastic containers?
   It is primarily used as a diluent for antibiotics, anesthetics, and reconstitution of injectable medications requiring sterilization in single-use plastic containers.

2. What protects the growth of BWFI in emerging markets?
   Expansion of healthcare infrastructure, increased pharmaceutical manufacturing, and rising demand for sterile injectable drugs support growth.

3. Which packaging material dominates the BWFI market?
   Plastic containers account for over 85% due to their cost-efficiency, lightweight nature, and safety features.

4. What are the primary risks facing the BWFI market?
   Regulatory hurdles, material compatibility issues, and supply chain disruptions pose significant challenges.

5. How are companies innovating in the BWFI segment?
   Focus areas include developing high-barrier plastics, preservative-free formulations, and integrated manufacturing for improved safety and compliance.

---

References

[1] Market Research Future. (2022). "Global Bacteriostatic Water for Injection Market Analysis."